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Abstract
Mucosal transmission of HIV is inefficient. The virus must breach physical barriers before it infects mucosal CD4
+ T cells. Low-
level viral replication occurs initially in mucosal CD4
+ T cells, but within days high-level replication occurs in Peyer’s patches,
the gut lamina propria and mesenteric lymph nodes. Understanding the early events in HIV transmission may provide
valuable information relevant to the development of an HIV vaccine. The viral quasispecies in a donor contracts through a
genetic bottleneck in the recipient, such that, in low-risk settings, infection is frequently established by a single founder
virus. Early-transmitting viruses in subtypes A and C mucosal transmission tend to encode gp120s with reduced numbers of
N-linked glycosylation sites at specific positions throughout the V1-V4 domains, relative to typical chronically replicating
isolates in the donor quasispecies. The transmission advantage gained by the absence of these N-linked glycosylation sites
is unknown. Using primary a4b7
+/CD4
+ T cells and a flow-cytometry based steady-state binding assay we show that the
removal of transmission-associated N-linked glycosylation sites results in large increases in the specific reactivity of gp120
for integrin- a4b7. High-affinity for integrin a4b7, although not found in many gp120s, was observed in early-transmitting
gp120s that we analyzed. Increased a4b7 affinity is mediated by sequences encoded in gp120 V1/V2. a4b7-reactivity was also
influenced by N-linked glycosylation sites located in C3/V4. These results suggest that the genetic bottleneck that occurs
after transmission may frequently involve a relative requirement for the productive infection of a4b7
+/CD4
+ T cells. Early-
transmitting gp120s were further distinguished by their dependence on avidity-effects to interact with CD4, suggesting that
these gp120s bear unusual structural features not present in many well-characterized gp120s derived from chronically
replicating viruses. Understanding the structural features that characterize early-transmitting gp120s may aid in the design
of an effective gp120-based subunit vaccine.
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Introduction
Despite widely available prevention modalities against HIV
transmission, 2.6 million individuals are newly infected with HIV
every year. Thus, there exists an urgent need for an effective HIV
vaccine. A number of studies that have focused on the earliest
events in HIV transmission raise the possibility that new strategies
for an effective vaccine immunogen can be developed.
HIV transmission following mucosal exposure is inefficient[1].
The virus must first breach physical barriers in the mucosa, and
then infect suitable target cells. In one study of heterosexual
couples discordant for HIV infection, the frequency of transmis-
sions per coital act averaged ,0.01 [2]. One can therefore infer
that, following deposition on the mucosal surface of the genital
tract, HIV very frequently fails to establish infection. Both human
and an SIV/macaque model studies indicate that during the first
days of infection, termed the ‘‘eclipse phase’’, low levels of viral
replication occur, primarily in suboptimally activated memory
CD4
+ T cells in the genital mucosa[3,4,5,6,7,8]. Although these
cells are metabolically active, they do not express classical
activation markers[4,7]. Subsequently, HIV-1 infects fully activat-
ed memory CD4
+ T cells. These events represent a critical point in
transmission because they lead to high-level replication and the
migration of virus into draining lymphoid tissue and ultimately
gut-associated lymphoid tissue (GALT) where activated CD4
+ T
cells are plentiful, viral replication amplifies and the high level
viremia that is associated with acute infection is established[9].
The best opportunity to prevent or abort establishment of HIV
infection is likely during the eclipse phase following transmission,
before HIV-1 migrates into the GALT.
A striking feature of sexual transmission of HIV is the extreme
restriction in the genetic diversity of the viral quasispecies shortly
PLoS Pathogens | www.plospathogens.org 1 February 2011 | Volume 7 | Issue 2 | e1001301after infection. The genetically diverse viral swarm replicating in
an infected transmitting partner constricts through a genetic
bottleneck in the course of sexual transmission such that
transmission is usually the result of a single infectious event; the
productive infection that follows, in most instances, reflects an
expansion from a single founder virus [10,11,12,13,14,15].
Importantly, this restriction occurs in the recipient, rather than
in the transmitting partner. The early progeny of the transmitted
founder virus show relative uniformity until adaptive immune
responses drive the founder to diversify into a quasispecies. An
instructive exception to this pattern occurs in recipients harboring
certain sexually transmitted diseases (STDs). Inflammation in the
genital mucosa, mediated by STDs, can promote transmission of
multiple founder viruses due predominantly to the ready
availability of activated CD4
+ T cell targets [10,12,16,17,18].
This underscores the crucial role that metabolically activated
CD4
+ T-cells likely play in transmission[19].
Considering that the early stages of HIV infection represent a
possible window of opportunity for preventing infection, the
structural, functional and immunogenic characteristics of founder/
early-transmitting gp120s are highly relevant to the design of a
preventive HIV vaccine. These viruses invariably utilize CCR5,
which is a key phenotype of early-transmitting gut-tropic
isolates[20,21]. The genotype of early-transmitting viruses has
also been a subject of great interest. Although a genotypic
signature of early-transmitting viruses has proved difficult to
identify, two key features have emerged. In studies of both
heterosexual and mother to child transmission, early-transmitting
gp120s have been found to be shorter in length, and encode fewer
potential N-linked glycosylation sites (PNGs) than typical chron-
ically replicating isolates[11,22,23]. These features have thus far
only been found in the context of infection with HIV subtypes A
and C. Length shortening has been observed in the V1/V2 region,
as well as V4 and flanking regions of gp120. PNGs absent from
early-transmitting isolates (PNGDs) appear in somewhat specific
positions around the N- and C-terminal stems of V1/V2[11,22]
and in C3/V4[24]. These characteristics apparently provide early-
transmitting isolates with increased transmission fitness[22,24];
however, the nature of this fitness-advantage is unknown. The
antigenic properties of early-transmitting isolates are the subject of
ongoing studies [25,26]. V1/V2, along with V4 and flanking
regions are frequently an early target of autologous neutralizing
antibodies (Nabs) [23,27,28]. The viral quasispecies escapes
neutralization through amino acid substitutions, insertions/
deletions (INDELs), and also by adding/shifting PNGs. In this
way the bulk of the quasispecies drifts away from the genotypic
features that distinguish early-transmitting isolates.
The V1/V2 domain of HIV-1 gp120 mediates binding to
integrin a4b7 (a4b7) on CD4
+ T-cells[29]. a4b7 has been termed
the gut homing integrin[30]. It is upregulated on lymphocytes in
Peyer’s patches and mesenteric lymph nodes, and then mediates,
in concert with chemokine receptors, the homing of these
lymphocytes into GALT through interactions with its natural
ligands, MadCAM and VCAM, which appear on gut endothelial
cells[31]. a4b7 appears in close association with the CD4 receptor
on mucosal CD4
+ T cells[32]. The biochemical characteristics of
the interactions between a4b7 and gp120 closely mimic those of
a4b7 with MadCAM and VCAM. There is a strong dependence of
this interaction on divalent cations, and the a4b7 binding-site in
V1/V2 shares close sequence homology with the binding sites of
a4b7’s natural ligands. This type of structural mimicry suggests
that the specific affinity of gp120 for a4b7 provides increased
fitness to HIV. However, unlike CD4 and CCR5, a4b7 is not
required for viral entry or replication in vitro.
a4b7
+/CCR5
+/CD4
+ memory T cells appear in the rectal and
vaginal mucosa[32,33]. In this way, this subset of CD4
+ T cells
links the portal of entry during sexual transmission and the
inductive and effector sites of the gut that provide a permissive
environment for near-exponential replication. We have proposed
that HIV evolved a specific affinity for a4b7 as a means of insuring
that productive target cells with gut-homing potential will be
infected shortly after transmission. We noted, however, that the
a4b7-reactivity of gp120s varied widely among isolates we
analyzed [29], suggesting to us that strong a4b7-reactivity might
provide increased transmission fitness over those isolates with
lower a4b7 –reactivity in the context of mucosal transmission.
In the present study we provide evidence that the apparent
selection at the time of mucosal transmission for viral envelopes
exhibiting transmission-linked PNGDs coincides with dramatic
increases in a4b7-reactivity. We conclude that a4b7-reactivity is
one of the phenotypes that can contribute to the genetic restriction
that occurs during mucosal transmission.
Results
Transmission linked PNGDs in gp120 increase affinity for
a4b7
Longitudinal studies of cohorts of couples discordant for HIV
infection have been used to isolate and characterize genotypic,
phenotypic and immunogenic properties of early-transmitting
gp120s. In studies involving heterosexual transmission of subtype
A and C viruses, early-transmitting viruses tend to encode more
compact variable loops of gp120 with reduced numbers of PNGs
relative to isolates replicating during the chronic phase of
infection[11,22,23]. This pattern represents a bias rather than a
rule, and although it is most frequently associated with the V1/V2
domain of gp120, the V4 and flanking regions of early replicating
viruses can also display these characteristics. In the V1/V2
domain, transmission-linked PNGDs are clustered at the N- and
C-termini of V1 and V2 respectively, while two central PNGs are
well conserved (Figure 1A). The apparent advantage that these
characteristics confer upon early-transmitting viruses is not known.
Author Summary
In the first days following sexual transmission, HIV
replication occurs initially at relatively low levels in
mucosal tissues because of a paucity of CD4
+ T cell targets
for the virus to infect. After a period of days, virus accesses
specific gut tissues that are enriched in activated CD4
+ T
cells, where near-exponential replication ensues. The
period of time before HIV accesses gut tissues represents
a window of opportunity where a microbicide, pre-
exposure and/or post-exposure antiretroviral prophylaxis
or a vaccine-induced immune response could block
infection. We previously reported that the HIV envelope
protein gp120 binds to integrin a4b7 on the surface of
CD4
+ T cells. a4b7 mediates the homing of CD4
+ T cells into
the gut tissues where HIV can replicate exponentially. Here
we report that the genotypic features that distinguish
viruses isolated within the first month after infection,
termed early-transmitting isolates, promote increased
steady-state reactivity with a4b7. This property likely
provides these viruses with enhanced transmission-fitness.
These results suggest that the infection of a4b7
+/CD4
+ T
cells can play an important role early in HIV transmission.
These findings have potentially important implications in
the design of interventions to block the mucosal
transmission of HIV.
a4b7
+/CD4
+ T Cells and Mucosal Transmission of HIV
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mediates gp120 binding to a4b7 [29]. We determined whether
removing PNGs in V1/V2 altered reactivity with a4b7. Two
recombinant gp120s, 92Ug037 (subtype A), and 93MW959,
(subtype C), were employed. Both envelopes were derived from
viruses obtained from asymptomatic females who contracted HIV-
1 through heterosexual transmission. 93MW959 was isolated ,12
months post-seroconversion, while the time between seroconver-
sion and isolation of 92Ug037 is unknown. PNGs were removed
by site-directed mutagenesis in which asparagines were replaced
with glutamines (Figure 1A). a4b7-reactivity was measured using a
steady-state binding assay that employs primary a4b7
+/CD4
+ T-
cells (Figure S1). Each PNG mutant was compared to its wild type
(w.t.) parent. For 92Ug037, PNGDs near the N-terminus of V1 or
the C-terminus of V2 mediated increases in a4b7-reactivity of up
to 20-fold (Figure 1B). For 93MW959, a single PNGD at the C-
terminus of V2 mediated a ,3.5-fold increase in a4b7-reactivity,
while PNGDs near the N-terminus of V1 had little effect on a4b7-
reactivity (Figure 1C).
Length-shortening in V1/V2 is also associated with early
transmitting gp120s. However, because those deletions often result
in PNGDs, it is difficult to determine whether short V1/V2s are
favored independently of PNGDs [34]. We examined the influence
of V1/V2 length shortening on a4b7-reactivity by taking
advantage of a previously characterized pair of subtype A
envelopes isolated from an individual at ,1-month and ,41-
months post-infection[23]. The month 1 V1/V2 (QA203M1)
encodes 63 amino acids and 5 PNGs, while the month 41 V1/V2
(QA203M41) encodes 70 amino acids and 8 PNGs such that the
41 month envelope encodes two additional PNGs near the N-
terminus of V1 and one additional PNG near the C-terminus of
V2 (Figure 2A). Both V1/V2s were grafted into a subtype A gp120
backbone isolated ,1year post-infection from a second patient.
QA203M1 gp120 displayed ,206 greater a4b7-reactivity than
did w.t. QA203M41 (Figure 2B). To distinguish the influence of
V1/V2 length from the influence of the number of PNGs on a4b7
reactivity we constructed a variant of the month-41 V1/V2
(QA203M41variant1) lacking the two V1 PNGs that were missing
in QA203M1 without changing its length (Figure 2A). QA203M41
variant 1, exhibited relatively strong binding to a4b7 that was
nearly identical to that of QA203M1 gp120. These results indicate
that increased a4b7-reactivity mediated by the early-transmitting
Figure 1. Effect of V1/V2 PNGDs on the a4b7-reactivities of a subtype A and a subtype C gp120. A) The V1/V2 regions of 92Ug037
(subtype A) and 93MW959 (subtype C) aligned with HXBII V1/V2. PNGDs associated with transmission are designated using HXBII numbering. PNGs
that appear in 92Ug037 and 93MW959 are highlighted in red. PNGDs introduced into each protein by N/Q substitution appear directly below. B)
a4b7-reactivities of 92Ug037 w.t. gp120 and PNGD mutants are reported as mean fluorescence intensity (MFI). C) a4b7-reactivities of 93MW959 w.t.
gp120 and PNGD mutants. Error bars report the standard deviation between two replicates, and results are representative of three independent
experiments using independent donor CD4
+ T cells.
doi:10.1371/journal.ppat.1001301.g001
a4b7
+/CD4
+ T Cells and Mucosal Transmission of HIV
PLoS Pathogens | www.plospathogens.org 3 February 2011 | Volume 7 | Issue 2 | e1001301QA203M1 relative to QA203M41 was due to PNGDs rather than
to a shorter V1/V2. We extended this analysis by removing
additional PNGs from QA203M41. QA203M41 variant 2 in
which PNGs were removed from the C-terminal region of V2
mediated a small increase in a4b7-reactivity, while QA203M41
variant 3, which combines variant 1 and variant 2 PNGDs
mediated an increase in a4b7-reactivity that was intermediate
between variant 1 and variant 2 (Figure 2A, C). These results
demonstrate that PNGDs do not necessarily enhance a4b7-
reactivity in an additive manner.
Taken together, analysis of all of the PNGDs described above
leads us to conclude that the removal of transmission-linked V1/
V2 PNGs can mediate large increases in the a4b7-reactivity of
both subtypes A and C gp120s. The pattern in which these
increases were mediated is complex such that no single PNGD at a
given position in V1/V2 mediated increased a4b7-reactivity in all
three gp120s. PNGDs near both the N- and C-termini of the V1/
V2 of 92Ug037 increased a4b7-reactivity, while only one PNGD
near the C-terminus of the V2 of 93MW959 increased a4b7-
reactivity. For QA203M41, the opposite was the case, removal of
V1 PNGs, but not V2 PNGs mediated a large increase in a4b7-
reactivity. These data suggest that increased a4b7-reactivity
mediated by PNGDs is due to changes in V1/V2 conformation
rather than through steric occlusion, a subject that will be
addressed below.
A study of early-transmitting viruses following mother to child
transmission reported that PNGs in the C3/V4 region of gp120
are also underrepresented in early replicating isolates in a manner
similar to that described above for V1/V2 PNGs [24]. Overbaugh
and colleagues found that PNGs at specific positions throughout
C3/V4 were underrepresented in early-transmitting isolates of
subtype A viruses isolated from infants shortly after birth.
Although this region of gp120 is far removed from the known
a4b7-binding site in V1/V2, we determined whether removing
these PNGs would also increase a4b7-reactivity. The C3/V4
region of 92Ug037 was aligned with subtype A sequences from the
study noted above and five transmission-linked 92Ug037 PNGD
gp120s were analyzed (Figure 3A). 92Ug037N333Q,
92Ug037N362Q, and 92Ug037N393Q gp120s mediated increas-
es in a4b7-reactivity of ,18 to 21-fold. Interestingly,
Ug037N355Q mediated a ,27-fold increase in a4b7-reactivity.
This increase was greater than that mediated by Ug037N144Q,
which among the 92Ug037 V1/V2 PNGDs mediated the largest
increase in a4b7-reactivity. 92Ug037N385Q mediated an ,8-fold
increase in a4b7-reactivity (Figure 3B). We conclude that, as with
V1/V2, PNGDs in C3/V4 can mediate large increases in a4b7-
reactivity. The increased a4b7-reactivity achieved by PNGDsi n
C3/V4 supports the proposition that the manner in which glycans
inhibit gp120 binding to a4b7 involves conformational changes in
gp120 rather than simple steric occlusion. Data supporting this
interpretation will be presented below.
Glycan type impacts gp120- a4b7 interactions
To better understand the role of glycan deletion in gp120-a4b7
interactions we compared the a4b7-reactivity of AN1 w.t. gp120, a
subtype B ancestral/consensus gp120[35], expressed in three
Figure 2. A comparison of the a4b7-reactivities mediated by the V1/V2 regions of a month-1 gp120 and month 41 gp120 isolated
from a single patient. A) The gp120 V1/V2 sequences from patient QA203 obtained at month 1 and month 41 are listed. PNGs are highlighted in
red. Variants, 1, 2 and 3 of QA203M41 are included with the N/Q substitutions highlighted in red. B) a4b7-reactivities of chimeric gp120s encoding the
V1/V2 regions of QA203M1, QA203M41 and QA203M41 variant 1 are reported as mean fluorescence intensity. C) A comparison of the a4b7-reactivities
of variants 1, 2 and 3 of QA203M41. QA203M41 is included for reference. Error bars represent the standard deviation of two replicates, and results are
representative of three independent experiments using independent donor CD4
+ T cells.
doi:10.1371/journal.ppat.1001301.g002
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AN1 w.t. was expressed in CHO S cells (a nonadherent subclone
of CHO K1), the same cell line in which all of the gp120s
described in the present study thus far were produced. gp120s
expressed in CHO K1 cells present a heterogeneous pattern of
oligo-mannose and complex carbohydrate type glycans [36].
Complex carbohydrates tend to appear on the solvent-exposed
loops, including V1/V2 of recombinant gp120 proteins [37]. We
also expressed AN1 gp120 in CHO lec1 cells, a CHO derivative
that lacks N-acetylglucosamine (GlcNAc) glycosyl transferase
activity, so that N-linked carbohydrate trimming is blocked at
the Man5-GlcNAc2-Asn intermediate (where Man is Man-
nose)[38]. gp120s produced in CHO lec1 cells are devoid of
complex carbohydrate, and are instead enriched with oligo-
mannose type glycans. Finally, we expressed AN1 w.t. gp120 in
293F cells (a nonadherent subclone of HEK 293T cells), which
differ from both CHO cell lines in the manner in which it modifies
complex carbohydrate. 293T derived cells sialylate the terminal
galactose moieties of complex carbohydrates through both a-2,3
and a-2,6 linkages. CHO cells, which lack a-2, 6-sialyltransferase,
establish these linkages only at the a-2,3 position [39]. CHO S
expressed AN1 w.t. gp120 reacted with a4b7 at an intermediate-
low level (Figure 4A), similar in magnitude to many of the gp120s
that we have previously reported[29]. CHO lec1-derived AN1 w.t.
gp120 reacted ,1006more efficiently with a4b7 than did CHO S
AN1 w.t. gp120 (Figure 4A). It is likely that this increase in a4b7-
reactivity results from the substitution of complex carbohydrates in
V1/V2 with oligo-mannose type glycans. In contrast, 293F
expressed AN1 w.t. gp120 showed no detectable a4b7-reactivity.
We subsequently analyzed six additional 293F and T derived
gp120s, including CAP881m.c17, a gp120 that exhibits very
strong a4b7-reactivity when derived in CHO S cells, and without
exception they all exhibited low or undetectable a4b7-reactivity
(Figure S2 and data not shown). Considering the differential
sialylation mediated by CHO S and 293 cells, we digested 293F
AN1 w.t. gp120 with neuraminidase, which catalyzes the
hydrolysis of terminal sialic acid residues; however, this failed to
rescue a4b7-reactivity (data not shown). We next expressed AN1
w.t. gp120 in 293F cells cultured in the presence of kifunensine, a
mannosidase I inhibitor that restricts the processing of N-linked
glycosylation beyond the Man9GlcNac2 intermediate and swain-
sonine, a mannosidase II inhibitor that restricts the processing of
N-linked glycosylation beyond hybrid glycan intermediates [40].
Expressing gp120 in 293F cells in the presence of these drugs
should, to some degree approximate the complex carbohydrate
deficient glycan characteristics of CHOlec1 derived gp120.
Neither drug rescued a4b7-reactivity (Figure 4A and data not
shown). Although we do not know what the post-translational
defect is in 293F and 293T-expressed gp120s, we conclude that
utilizing gp120s produced in this manner may not be ideal for
studies involving a4b7.
We next determined what effect restricting the glycans on AN1
w.t. gp120 to the oligo-mannose type, as occurs in CHO lec1 cells,
would have compared to the effect of the deletion of transmission-
linked glycans in AN1 derived from CHO K1 cells. Three AN1
PNGD derivatives: AN1 NN140/143QQ, AN1 N204Q, and the
combined mutant AN1 NN140/143QQ,N204Q, were expressed
in CHO-S cells (Figure 4B). These PNGs appear near the N- and
C-termini of V1 and V2 and their positions correspond to
transmission-linked PNGs. Compared to AN1 w.t. expressed in
CHO-S cells, AN1 NN140/143QQ increased a4b7-reactivity by
,25-fold (Figure 4A). AN1 N204Q increased a4b7-reactivity by
,23-fold. The combined mutant NN140/143QQ,N204Q in-
creased a4b7-reactivity by ,96-fold, and resulted in a CHO-S
Figure 3. Effect of PNGDs in the C3/V4 region on the a4b7-reactivity of 92Ug037 gp120. A) The positions of transmission-linked PNGs in
the C3/V4 region of subtype A gp120s are highlighted in red in the C3/V4 region of 92Ug037 and N/Q substitutions are listed directly below. B) a4b7-
reactivity of each 92Ug037 PNGD mutant was compared to w.t 92Ug037 gp120 and reported as mean fluorescence intensity (MFI) 92Ug037N144Q
was included for reference. Results are representative of three independent experiments using independent donor CD4
+ T cells.
doi:10.1371/journal.ppat.1001301.g003
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gp120. To formally demonstrate that increased a4b7-reactivity can
result from reduced N-linked glycosylation we carried out a brief
digestions of CHOlec1 derived AN1 gp120 with endoglycosidase
H (Endo-b-N-acetylglucosaminidase H) and determined that the
enzymatic removal of PNGs from AN1 gp120 leads to increased
a4b7-reactivity (Figure S3). Overall these results demonstrate that
different glycosylation patterns mediated by different cells can
exert a strong influence on a4b7-reactivity. In the case of AN1
gp120, replacing complex carbohydrate with oligo-mannose type
glycans mediates stronger a4b7-reactivity, but this same strong
binding can be achieved by deleting a small number of PNGs in
V1/V2.
a4b7 –Reactivity and escape from autologous
neutralizing antibodies
A pseudotyped virus encoding the month 1 QA203M1 V1/V2,
described above (Figure 2), was efficiently neutralized by autologous
serum taken at month 40, while a pseudotyped month 41
QA203M41 virus escapes neutralization from this same serum[23],
indicating that neutralization-escape in the 40 month isolate was
mediated by V1/V2. This pattern of escape is somewhat typical of
early- vs. chronic-replicating HIV-1 viruses and reflects the fact that
in subtype A and C viruses V1/V2 is frequently a direct target of
early autologous neutralizing antibodies[23,27,28]. Additionally,
V1/V2 can mediate a second type of neutralization-escape that
affects epitopes throughout gp120. Mutations in V1/V2 can
Figure 4. Effect of glycan content on the a4b7-reactivity. A) a4b7-reactivity of the ancestral AN1 gp120 (subtype B) produced in CHO-S cells,
293F cells, CHO lec1 cells and kifunensine treated 293F cells, were compared and reported as mean fluorescence intensity (MFI). AN1 V1/V2 PNGDs
were also included. Results are representative of three independent experiments using independent donor CD4
+ T cells. B) Positions of all PNGs and
the a4b7 binding site in the V1/V2 loop of AN1 gp120 are illustrated.
doi:10.1371/journal.ppat.1001301.g004
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conformational masking[41,42,43,44]. Both mechanisms of escape
are mediated by a combination of sequence variation, INDELS,
and the addition and/or position-shifting of PNGs. We questioned
whether changes in gp120 leading to neutralization-escape would
disrupt a4b7-reactivity. Two recent studies [27,28], in which
quasispecies evolution and autologous neutralizing Ab responses
were followed longitudinally, beginning shortly after transmission,
provide perhaps the best-defined examples of V1/V2-mediated
escape. Rong, Derdeyn and colleagues[28], demonstrated that the
antibodies present in an HIV-1 subtype C infected female patient
(patient 205F) at ,38 months post-infection neutralized the early-
replicating founder virus isolated within the first month following
sexual transmission. Importantly, virtually all of the neutralizing
activity in the 38-month sera targeted V1/V2 dependent epitopes.
In a second study Moore, Morris and colleagues describe a more
complex pattern of neutralization-escape[27], in which the early-
transmitting month 1 virus isolated from a female patient, CAP88
(subtype C), was sensitive to autologous serum taken after 13
months, while viruses replicating at month 12 were not. Month 12
isolates were able to escape the month 13 sera via INDELS and
PNG additions in both V1/V2 and C3.
We produced the neutralization sensitive 205F 0-month founder
gp120 (Z205F.ENV1.1), and four escape mutants. The 0- and 8-
month escape viruses are highly sensitive to neutralization by 38-
month plasma and this escape was mediated by sequence changes
that lie entirely within V1/V2 (Figure S4). The two 38-month
viruses are partially resistant to neutralization by 38-month
autologous plasma. The 205FENV1.1 0-month founder exhibited
,8-fold greater a4b7–reactivity than did the 0-month escape, and
at least 17-fold greater than did the 8- and 38-month escape
gp120s (Figure 5A). The level of a4b7-reactivity exhibited by the
205F.ENV1.1 0-month founder appeared to be substantially
greater than many of the w.t. gp120s we previously reported[29].
We conclude that the high level of a4b7 reactivity in the 0-month
founder was lost concomitant with sequence changes that
mediated neutralization-escape.
We next compared the a4b7-reactivity of CAP88 gp120s
isolated at 1 month and 12 months post infection. We chose
CAP88.1m.c17, which reflects the predominant circulating isolate
early in the first month post-infection. We also expressed the 12
month isolate CAP88.12m.c2 that diverged from CAP88.1m.c17
by adding PNGs in both V1/V2 and C3 at positions that
correspond to transmission-linked glycans (Figure S4). The
addition of these PNGs was shown to contribute to the resistance
of CAP88.12m.c2 to autologous serum taken after month 13[27].
Like the 205F 0 month founder, CAP88.1m.c17 exhibited strong
a4b7 reactivity (Figure 5B). Surprisingly this high level of reactivity
was maintained in CAP88.12m.c2 despite the fact that PNGs were
added at transmission-linked PNG positions in both V1/V2 and
C3. This result demonstrates that viruses with relatively strong
a4b7-reactivity can escape from autologous neutralizing antibodies
without losing their a4b7-reactivity. Considering the complex
pattern of changes in a4b7-reactivity we observed with the various
N/Q substitutions described in Figures 1, 2 and 4, in which no
single PNGD generated the same effect on each of the proteins
analyzed, we conclude that the glycans that can mediate
neutralization-escape may impact a4b7 reactivity (e.g. 205F), but
not in all gp120s, and not in a way that is easily predictable.
In summary, we find that both of the early-replicating gp120s
we analyzed showed high levels of a4b7-reactivity. Escape from
neutralizing antibodies disrupted this activity in gp120s derived
from patient 205F, but the a4b7-reactivity of a gp120 derived from
patient CAP88 persisted 12 months post-infection despite
sequence changes in V1/V2 and C3 that mediated escape from
autologous neutralizing antibodies.
a4b7-Reactivity in relation to CD4 affinity
The affinity of HIV-1 gp120s for CD4 varies over a wide range
and these differences can influence the cell-tropism of a viral isolate.
Figure 5. a4b7-reactivity of early-transmitting gp120s. A) gp120s
corresponding to patient 205F 0 month founder, 0 month escape, 8
month escape and two 38 month escape viruses were assayed for a4b7-
reactivity and reported as mean fluorescence intensity (MFI). B) gp120s
corresponding to a 1 month virus and a 12 month virus isolated from
patient CAP88 were assayed for a4b7-reactivity and reported as mean
fluorescence intensity (MFI). A consensus/ancestor subtype C gp120
was included for reference. Error bars represent the standard deviation
of two replicates, and results are representative of three independent
experiments using independent donor CD4
+ T cells.
doi:10.1371/journal.ppat.1001301.g005
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phages by compensating for the low density of CD4 appearing on
the macrophage membrane[45]. Changes in CD4 affinity could
theoretically impact the transmissibility of a viral isolate; however,
studies of early replicating gp120s have not, to date, found any clear
correlation between CD4 affinity and transmission fitness [25].
Numerous studies have, however, shown that both amino acid
substitutions and glycan additions/deletions in V1/V2 can
influence the conformation of gp120 in a global way [44,46].
Because V1/V2 plays an important role in a4b7 recognition we
determined whether there was any relationship between a4b7-
reactivity and CD4-reactivity. We first employed a steady-state
bindingassaytocompare thereactivityofgp120sfora4b7and CD4.
In this assay, retinoic acid-cultured CD4
+ T cells were differentially
masked with either a CD4 mAb or an a4 mAb, as described in
supporting Figure S1. For gp120s derived from early-transmitting
viruses we found that a4b7 mediated a greater degree of binding to
the cell surface than did CD4. The amount of 205F 0-month
founder gp120 bound to a4b7 was 37-fold greater than that bound
to CD4, but this differential disappeared in each of the 205F escape
gp120s (Figure 6A). Such differences could be mediated entirely by
V1/V2, as demonstrated by comparing the CD4- and a4b7-
reactivities of the chimeric QA203M1 and QA203M41 gp120s,
which are identical in all domains other than V1/V2. 1-month
QA203M1 bound 5-fold more to a4b7 than to CD4 while the 41
month QA203M41 was captured primarily by CD4 (Figure 6B).
The deletion of a single transmission-linked PNG was sufficient to
achieve a binding profile in which more binding to the cell
membrane was mediated by a4b7 than by CD4. For example, while
the majority of w.t. 92Ug037 binding to the cell surface was
mediated by CD4, PNGDs at the N terminus of V1/V2 altered this
pattern such that more binding was now mediated by a4b7
(Figure 6C).Finally,we comparedthetwoCAP88gp120stoa panel
that included several widely studied gp120s and subtypes B and C
ancestral/consensus gp120s[35,47]. Similar to the 205F 0 month
founder and the chimeric QA203M1, both CAP88 proteins showed
preferential binding to a4b7 over CD4 (Figure 6D). In contrast to
the CAP88 gp120s, all other gp120s in the panel, with one
exception, exhibited CD4 binding that was equal to or greater than
a4b7 binding. The one exception was SF162, a highly neutraliza-
tion-sensitive gp120 whose gut tropic characteristics have been well-
documented[20,21]. Because levels of a4b7 expression on the cells
we employed were equivalent to, or less than CD4 expression levels
(Figure 6 inset and Materials and Methods) we can conclude that
the steady-state affinity of gp120s, like the two CAP88 proteins, for
Mn
++ activated a4b7 is greater than their steady-state affinity for
Figure 6. A comparison of steady-state CD4-reactivity and a4b7-reactivity of a panel of gp120s. A) Levels of CD4-reactivity (red) and a4b7-
reactivity (blue) were assessed for each patient 205F gp120, B) the QA203 month 1 and month 41 chimeric gp120s, C) w.t. and N144Q 92Ug037
gp120s, D) the 1-month and 12 month CAP88 gp120s and a panel of well characterized gp120s including an ancestral B (AN1) and an ancestral C
(ANC1) gp120. Inset indicates the staining of the cells employed in this assay with PE conjugated CD4 (red) and b7 (blue) mAbs. Error bars represent
the standard deviation of two replicates, and results are representative of three independent experiments using independent donor CD4
+ T cells.
doi:10.1371/journal.ppat.1001301.g006
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reactivity of the early-replicating gp120s we analyzed, relative to a
number of well-studied gp120s. In this way, these gp120s appear to
be better adapted to interact with CD4
+ T cells that express a gut-
homing receptor.
It is noteworthy that the large changes in steady-state binding to
a4b7, mediated by sequence changes in V1/V2, were coupled with
relatively small changes in steady-state binding to CD4 (Figure 6).
In some HIV-1 isolates, insensitivity to sCD4 and CD4 binding-
site antibody neutralization is mediated by V1/V2 [44,46], a
phenomenon termed conformational masking[41,42,43]. Of note,
this masking-effect can be modulated by the same transmission-
linked PNGs that exert a strong influence on a4b7-reactivity
[44,46]. To better understand the relationship between CD4-
reactivity, V1/V2 masking, and a4b7-reactivity we employed a
surface plasmon resonance-based kinetic CD4 binding assay.
gp120s were immobilized on the surface of a biosensor chip and
either monomeric sCD4 (D1D2), or D1D2-Ig atp, a highly
oligomerized (dodecameric) CD4-Ig derivative[48,49,50], was
passed over the surface, allowing us to measure reaction kinetics
(Figure 7A). In this format D1D2-Ig atp can bind .1 gp120 in a
near-simultaneous manner, allowing avidity-effects to contribute
to interactions between it and gp120. However, in this format,
avidity cannot contribute to monomeric sCD4-gp120 interactions.
Sensorgrams of nine well-studied gp120s, including JR-FL gp120
(Figure 7B), and eight additional gp120s (Figure S5) are provided
for reference. 205FENV1.1 0-month founder gp120 failed to
recognize monomeric CD4, but did exhibit high affinity for
dodecameric D1D2-Igatp (Figure 7C). The failure of this gp120 to
react with monomeric CD4 distinguishes it from the nine standard
gp120s we analyzed (Figure 7B and Figure S5). However, we
observed the same phenomenon with the1-month QA203M1
chimeric gp120 (Figure 7D), and CAP88 1m.c17(Figure 7E). In
patient 205F and QA203 reactivity with monomeric sCD4
reappeared as the viral quasispecies evolved away from the early
transmitting isolate. Both the 38 month 205F.ENV5.1 gp120
(Figure 7C) and 41 month QA203M41(Figure 7D), which bind
weakly to a4b7, did bind monomeric sCD4 with high-affinity. In
summary, all three early-transmitting gp120s failed to react with
monomeric sCD4, which distinguishes them from nine standard
gp120s. Because the chimeric QA203M41 and QA203M1 gp120s
differ only in V1/V2 we conclude that the failure of QA203M1 to
bind monomeric sCD4 was mediated by V1/V2, and it seems
likely that this also holds for 205F.ENV1.1 0-month founder, and
CAP88 1m.c17. All three of these gp120s did, however, react with
dodecameric D1D2-Igatp (Figure 7 C, D, E), and with CD4
displayed on the surface of a T cell (Figure 6). The failure to
interact with monomeric sCD4 in this SPR based assay does not
indicate that the viruses from which these gp120s were derived are
CD4-independent, nor can one conclude that these viruses would
be resistant to sCD4 neutralization. This observation does indicate
that the CD4-reactivity of these early-replicating gp120s is more
dependent on avidity-effects than is the case for the other gp120s
that we analyzed, and further suggests that, in addition to high-
level a4b7-reactivity, these gp120s share structural features that
distinguish them from many gp120s. Although these distinguishing
biochemical features involve gp120 monomers, it is reasonable to
suggest that these features will in some manner impact the stability
and immunogenicity of trimeric spikes[51].
Discussion
The search for a consistent genotypic signature of early-
transmitting viruses has proven difficult. The most consistently
observed genotypic marker thus far identified is a more compact
V1–V4 with a reduction in the number of PNGs, relative to the
length and average number of PNGs in chronically replicating
isolates[11,22,23]. Early-transmitting viruses bearing this genotype
do not appear to use CD4 or CCR5 in any way that distinguishes
them clearly from chronically replicating isolates[25,52]. Howev-
er, we found that removing transmission-linked PNGs from
multiple gp120s consistently resulted in greatly increased a4b7-
reactivity. Additionally, the early-transmitting gp120s that we
analyzed showed notably higher levels of a4b7-reactivity than
many of the chronically replicating isolates that we assayed. These
results suggest that increased a4b7-reactivity is likely to be part of
the phenotype underlying PNGDs in some early- transmitting
viruses and that this increased reactivity provides, under certain
conditions, increased fitness in the process of transmission. Under
this scenario, engaging a4b7 could provide an advantage at an
early stage of transmission, but may not always be required. We
should emphasize that additional analyses, that include greater
numbers of early-transmitting gp120s are needed to better
estimate the importance of a4b7
+/CD4
+ T-cells in mucosal
transmission. Moreover, we do not yet know the specific point
in the process of transmission where a4b7-reactivity may have an
impact, nor do we know the relative importance of a4b7-reactivity
on transmission fitness relative to other phenotypic features of
gp120. However, the fact that HIV has evolved an affinity for a4b7
reflects the important role that a4b7
+/CD4
+ T-cells likely play in
the process of mucosal transmission. This is of potential
importance since it follows logically that blocking viruses from
infecting these cells will reduce the frequency of successful
transmission.
We analyzed only two early-transmitting gp120s and one early-
transmitting chimera. Clearly, we cannot generalize from this
small number, yet it is noteworthy that all three envelopes bind
more efficiently to activated a4b7 than to CD4. Thus, these gp120s
are better adapted to interact with a4b7
+/CD4
+ T cells as opposed
to a4b7
lo-neg/CD4
+ T cells. We previously reported that
metabolically activated cells are enriched in the a4b7
+ subset of
CD4
+ T cells in rectal mucosa[32], and a similar observation has
been made for cervical a4b7
+/CD4
+ T cells (R. Kaul, personal
communication). CD4 is not a marker of cellular activation or of
gut-homing. When the affinity of a gp120 for CD4 is high, e.g. JR-
FL gp120, it engages all CD4 cells regardless of their metabolic
state or homing potential. CCR5 expression can correlate with
metabolic activity; however, prior to CD4-binding it is hidden
from HIV. By increasing a4b7-reactivity, which is CD4-indepen-
dent, we find that the early-transmitting gp120s that we analyzed
are better adapted to engage with a specific subset of CD4
+ T cells
that are highly susceptible to infection by both HIV and
SIV[32,53], and located in anatomical sites relevant to HIV
transmission. The context in which the interaction between HIV-1
and a4b7
+/CD4
+ T cells takes place remains unclear. It may
involve cell-free virions, but it might also occur in the context of
dendritic cell-CD4
+ T cell interactions that are potentially
important in mucosal transmission[54]. With one exception
(SF162 gp120), none of the commonly studied gp120s that we
characterized here or in our previous report exhibited this
phenotype[29]. Although these standard gp120s may not neces-
sarily be representative of chronic HIV isolates, it is noteworthy
that several showed near-undetectable a4b7-reactivity. This is
consistent with our previous observation that a4b7 interactions are
not required for viral replication[29] and underscores the fact that
a4b7-reactivity can diminish rapidly in a newly infected individual
(e.g. patient 205F). We note, however, that the introduction of a
small number of transmission-linked PNGDs into a gp120 derived
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generate a strong a4b7-reactive phenotype such that this gp120 is
now better adapted to engage CD4
+ T cells that express a4b7.
Because these transmission-linked PNGDs have been found in a
somewhat consistent manner in early-transmitting gp120s in
multiple studies involving transmission of subtypes A and C
viruses [11,22,23,24,55], it will be important in future studies to
determine the extent to which strong a4b7-reactivity is a
phenotype that is overrepresented in early-transmitting isolates.
It will also be important to determine the frequency with which
early-replicating viruses bind more efficiently to activated a4b7
than to CD4.
The frequency and circumstances under which viruses encoding
fewer PNGs in V1–V4 are preferentially established in a newly
infected individual provides clues concerning the possible role of
gp120-a4b7 interactions in facilitating mucosal transmission. We
note that transmission-linked PNGDs have thus far been found
only in cohorts of heterosexual couples discordant for HIV
infection and a mother to child transmission cohort, all of which
involve subtypes A and C, but not B[56]. The failure to observe
this genotypic pattern in subtype B cohorts may reflect differences
in the predominant modes of transmission i.e. heterosexual
transmission versus transmission among men who have sex with
men and intravenous drug users. It may also reflect other
Figure 7. CD4 binding characteristics of early-transmitting gp120s. A) Schematic of the Surface Plasmon resonance analysis strategy used to
measure the reactivity of monomeric sCD4 (D1D2) and dodecameric sCD4 (D1D2-Igatp). B–E) Sensorgrams depicting the binding kinetics of
increasing concentrations of D1D2 or D1D2-Igatp reacting with immobilized gp120s, the identities of which are noted in each panel. Each ligand/
analyte pair is listed and overall affinity is reported as KD (where applicable). These results are representative of three independent experiments using
independently coupled gp120 biosensor surfaces.
doi:10.1371/journal.ppat.1001301.g007
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may play a greater role under conditions in which the risk of
acquisition is low, but less of a role when that risk is high. One risk
factor that can influence susceptibility to infection is the presence
of STDs that cause inflammation of genital tissues in a recipient
[10,12,16,17,18]. To the extent that inflammation increases the
availability of activated CD4
+ T cells near the site of infection, the
selection pressure for a virus with strong a4b7-reactivity may be
diminished. However, an opposite dynamic may also be operative
under different circumstances. Chlamydia infection (and possibly
other STDs) in the female genital tract has been shown to increase
the number of antigen-specific a4b7
+ T cells migrating through the
female genital tract and into GALT[33,57,58,59]. Under these
conditions, isolates that can bind a4b7 are more likely to engage
activated CD4
+ T cells. Further phenotypic characterization of
a4b7
+ T cells in mucosal tissues, as well as the early-transmitting
viruses derived from different types of transmission cohorts, will be
necessary to clarify the relationship between acquisition risk factors
and a4b7-reactivity.
We found that the type of glycans that decorate gp120 can exert
a strong influence on a4b7-reactivity. By producing gp120 in a cell
that fails to process oligomannose glycans into larger complex
glycans we were able to increase the a4b7-reactivity of AN1 gp120
by .100-fold. In this regard, it is well established that different cell
types, and even the same cell type, under different metabolic
conditions, glycosylate proteins differently [60,61]. We know that
gp120s produced in macrophages are glycosylated differently than
the same gp120s produced in CD4
+ T cells[62]. It follows then
that a4b7-reactivity, and possibly the transmissibility of a virion,
may be influenced by the type of cell in which that virion is
produced in vivo. It would be useful if we could tailor our in vitro
gp120 expression systems in a way that reflects in vivo glycosylation;
however, although a recent study has characterized the glycan
content presented on virion-associated spikes generated in primary
PBMCs in vitro [63], we do not yet know the true glycan profile of
any in vivo derived HIV-1 gp120. In addition to glycosylation,
other post-translational modifications may also influence a4b7-
reactivity. We found that gp120s produced in 293F and 293T cells
showed greatly reduced a4b7-reactivity, which could not be
explained entirely by differences in glycosylation. These observa-
tions may prove useful in evaluating the limitations of 293-derived
gp120 for transmission-related studies. Overall these data indicate
that post-translational modifications in gp120 have the potential to
influence the transmissibility of HIV-1, and that the type of
carbohydrate that appears on an envelope may play a critical role
in the selection of early-transmitting isolates.
Although certain PNGs in V1/V2 may sterically interfere with
gp120 binding to a4b7, the manner in which transmission-linked
PNGDs throughout V1–V4 increased a4b7-reactivity suggests that
increased a4b7-reactivity resulted from a change in the confor-
mational state(s) of gp120. In this regard, it is well established that
V1-V4 glycans can influence gp120 conformation globally[64,65].
In addition, it is noteworthy that the naturally occurring gp120s
that we analyzed exhibited either strong or weak a4b7-reactivity,
since it suggests that there is a distinct conformational or structural
feature associated with some early-transmitting gp120s that allows
them to engage a4b7 in an efficient way. It is highly likely that
sequence changes independent from PNGs will also influence
a4b7-reactivity. In fact, the relatively high level of a4b7-reactivity
exhibited by the 205F 0-month founder gp120 when compared to
later isolates from this patient cannot be explained by a reduced
number of PNGs. This underscores the limitation of using a
genotypic feature i.e. the number of PNGs, to predict a phenotype.
As more sequence information involving early-replicating isolates
becomes available, and additional genotypic signatures are
identified, it will be interesting to determine how they influence
a4b7-reactivity. The number of gp120s analyzed here is small;
therefore, it will be important to analyze the a4b7-reactivity of
additional early-transmitting gp120s. Definition of the distinguish-
ing features of early-transmitting gp120s is clearly relevant to
subunit-based vaccine design.
The influence that PNGs can exert on gp120 structure and
immunogenicity has been well studied[66]. The transmission-
linked glycans in V1/V2 can, when they are present on a gp120,
promote conformational masking. This term is used to describe
the capacity of V1/V2 to increase the resistance of HIV-1 isolates
to neutralizing antibodies with specificities throughout
gp120[41,42,43,44]. This effect has also been referred to as
‘‘entropic masking’’ or ‘‘flickering’’, both of which describe the
property of envelope spikes to rapidly transition between alternate
conformations. Rapidly alternating conformations has the net
effect of reducing the apparent affinity of neutralizing gp120
antibodies. We find that PNGs, which have been shown to
promote conformational masking [44,46], are among those that
can influence a4b7-reactivity. The manner in which high affinity
for a4b7 is related to conformational masking is an important
question that requires further investigation. In any case, our
demonstration that the early-transmitting gp120s we analyzed
(205F.ENV1.1 0 month founder, CAP88.1m and QA203M1) rely
on avidity effects to engage sCD4 suggests that there are structural
properties that distinguish these gp120s from many commonly
studied gp120s.
Finally, apart from the early-transmitting gp120s, strong a4b7-
reactivity was infrequent among the panel of gp120s that we
analyzed. This raises the question as to how frequently viruses
bearing this phenotype appear in the viral quasispecies throughout
the course of HIV disease. It may be that they appear
spontaneously. This seems to be the case in patient 205F in
which only the early-transmitting 0 month founder exhibited
strong a4b7-reactivity. It is also possible that viruses bearing this
phenotype are compartmentalized in mucosal tissues such that
sampling virus from peripheral blood may lead to an underesti-
mation of their frequency. In this regard, it is important to
understand how frequently these viruses appear in the donor
genital fluids from which virus is transferred to a recipient during
sexual transmission.
In conclusion, the transmission-linked PNGDs that characterize
some early-transmitting HIV-1 gp120s mediate a phenotype that
includes increased a4b7-reactivity, suggesting that virions that
react strongly with a4b7 may possess increased transmission-
fitness. Further studies will be required to establish a direct link
between a4b7-reactivity and increased transmission across mucosal
surfaces. Our observations also suggest that a4b7
+/CD4
+ T-cells
are an important target population in the process of transmission.
The gp120s we analyzed that exhibited strong a4b7-reactivity
interacted with sCD4 in a way that distinguishes them from many
gp120s, and suggests that early-transmitting gp120s bear structural
features that might be exploited in the context of a subunit
vaccine. Additional genotypic, phenotypic and structural analyses
of early-transmitting viral envelopes are essential.
Materials and Methods
Ethics statement
PBMCs were collected from healthy donors through a NIH
Department of Transfusion Medicine protocol that was approved
by the Institutional Review Board of the National Institute of
Allergy and Infectious Diseases, National Institutes of Health.
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Cells and reagents
Freshly isolated PBMCs were obtained from healthy donors and
separated by Ficoll-Hypaque. Purified CD4
+ T cells were obtained
by negative selection using magnetic beads (StemCell Technolo-
gies). Cultured CD4
+ T cells were activated with OKT3, IL2
(20 IU/ml) and retinoic acid (10 nM) unless otherwise specified.
RA was obtained from Sigma Chemical and discarded 1-month
after reconstitution. CHO lec1 cells and HEK293T cells were
obtained from ATCC. CHO-S and 293F cells were obtained from
Invitrogen. Integrin antibodies were purchased from BD Biosci-
ences, Beckman Coulter and R&D. Leu3A (SK3) and CD45RO
were purchased from BD Biosciences.
Recombinant envelope proteins
The genbank accession numbers of all gp120s used in this study
are listed below. The QA203M1 and QA203M41 chimeric
gp120s were constructed by inserting the V1/V2 sequences
of each of these gp120s into a Q23 backbone. QA203M1:
VTLECSNVNVTNNVTNDMGEEIKNCSFNMTTELRDK-
KQKTYSLFYKLDVVPFNNRSQYRLIN. QA203M41: VTLEC-
SNVNVTNNVNVTNNVNVTNNVTNDMTGEIKNCSF-
NMTTELRDKKQKVYSLFYKLDVVPVNNNSSQYRLIN. All
gp120 coding sequences were synthesized and codon-optimized for
expression in mammalian cells (DNA2.0). All proteins were
produced and purified in an identical manner unless noted
otherwise. The mature coding sequences of each envelope protein,
from +1 to the gp120-gp41 junction were inserted into a
mammalian expression vector downstream of a synthetic leader
sequence. Vectors were transiently transfected into either 293F or
CHO-S cells (Invitrogen) using FreeStyle MAX Reagent (Invitro-
gen) per the manufacturers instructions. gp120s expressed in
CHOlec1 cells were transfected by CaPO4 and stable cell lines
were selected in media containing 1 mg/ml G418. Clonal cell lines
were established and subsequently seeded into hollow-fiber
cartridges (30 kD MW cutoff) (Fibercell systems, Frederick MD).
Protein containing supernatants were harvested daily from the
extra-capillary space. Protein containing supernatants were har-
vested and passed over a column of galanthus nivalis lectin sepharose
(Vector Labs) which was diluted 1:5 with unliganded sepharose 4B
to minimize avid binding. gp120 was eluted with 20 mM Glycine-
HCl, pH 2.5, 150 mM NaCl, 500 mM a-methyl-manno pyrano-
side (Sigma), in 5 mL fractions directly into 1 mL M Tris-HCL,
pH 8.0. Low pH elution was found to be necessary with certain
gp120s which bound too tightly to the lectin to be efficiently eluted
using a-methyl-manno pyranoside. Peak fractions were pooled,
concentrated with a stirred cell concentrator (Millipore) and
dialyzed exhaustively against HEPES, pH 7.4, 150 mM NaCl.
Proteins were quantitated by UV adsorption at O.D. l280
(extinction coefficient 1.1) and values were confirmed by a
bicinchoninic acid protein assay (Pierce).
Recombinant gp120 protein labeling
Purified recombinant gp120s were biotinylated using amine-
coupling chemistry. Proteins were reacted with a 100-fold molar
excess of EZ-Link NHS-Biotin (Pierce) for 30 min, and reactions
were quenched by rapid buffer-exchange into HBS. Biotin
incorporation was determined by reacting gp120s with 49-
hydroxyazobenzene-2-carboxylic acid-avidin conjugates (HABA)
per the manufacturers instructions (Pierce). Protein preparations
exhibiting a 1.0–1.2 mol/mole, biotin/gp120 incorporation were
used in comparative semi-quantitative flow-cytometric binding
assays.
Flow cytometry binding assays
CD4
+ T cells were cultured in RA for at least 6 days prior to
use, and were stained with fluoresceinated anti b7 mAb FIB27
(ATCC) to insure RA-mediated upregulation of a4b7. Receptor
quantitation using anti-mouse IgG coated microbead analysis of
CD4 and b7 expression levels of these cells from multiple donors
indicates that levels of b7 expressed on the surface of these cells
typically lower and less uniform than CD4 expression levels (data
not shown). The entire staining procedure, including wash steps
was carried out in a 10 mM HEPES, 150 mM NaCl (HBS Buffer)
buffer containing 100 mM CaCl2 and 1 mM MnCl2. Cells were
pre-blocked with normal mouse IgG and human IgG (5 mg each
per 10
6 cells. 3610
5 cells were stained in a volume of 50 ml on ice.
Where indicated CD4-gp120 interactions were masked by
preincubating cells for 159 with 5 mg Leu3A (SK3) (Becton
Dickinson). Where indicated a4b7-gp120 interactions were masked
with 5 mg unlabeled a4 mAb HP2/1 (Beckman Coulter). Masking
antibodies were not washed away prior to gp120 staining. Biotin
gp120 was added for 259 on ice, after which cells were washed
twice with staining buffer. In some assays CD45RO FITC and
CCR5 APC were included, Neutravidin PE (Pierce) was then
added, and incubation proceeded for an additional 309 on ice.
Cells were washed three times in staining buffer and then fixed in a
1% paraformaldehyde solution. Data were acquired using a BD
FACSCalibur and mean fluorescence intensity measurements
were obtained from the CD45RO
+/CCR5
+ gate.
Surface plasmon resonance analysis
Analysis was performed on a Biacore 3000 instrument (GE Life
Sciences) using CM5 sensor chips. The data were evaluated using
BIAevaluation 4.1 software (GE Life Sciences). The chip surface
was activated by injecting 35 ml of a 1/1 mixture of 0.05 M N-
hydroxysuccinimide and 0.2 M N-ethyl-N-(dimethylaminopropyl)-
carbodiimide at 5 ml/min. Purified gp120 (5 mg/ml in 10 mM
NaOAc (pH 5)) was immobilized to a density of approximately
750 resonance units (RU) and blocked with 35 ml of 1 M Tris-HCl
(pH 8.0). Human IgG was immobilized to one flow cell and used
as a background control. Running buffer was HBS (pH 7.4),
0.005% Tween p20. To evaluate Env: CD4 interactions,
increasing concentrations of sCD4 (D1D2) (6.25–400 nM) were
sequentially injected over surface-bound gp120 at a flow rate of
25 ml/min. After a 2 min injection of sCD4, the surface was
washed for 2 min in running buffer to follow the dissociation of
sCD4 from gp120. The surfaces were regenerated by injection of
4.5 M MgCl2 at a flow rate of 50 ml/min.
Genbank accession numbers of gp120s
The following gp120s were employed in these studies: 93MW959
(GenBank accession # U08453, R5-tropic), 92TH14-12 (GenBank
accession #U08801, R5-tropic), 93Ug037 (GenBank accession #
U51190, R5-tropic), AN1 gp120 [35] (sequence available at http://
ubik.mullins.microbiol.washington.edu/HIV/Doria-Rose2005/,
R5-tropic), 92Ug21-9 (GenBank accession # U08804, X4-tropic).),
ADA (GenBank accession #AF004394, R5-tropic), YU-2 (Gen-
Bank accession #M93258, R5-tropic), NL4-3 (GenBank accession
# AF003887, X4-tropic), 92Ug21-9 (GenBank accession
#AY669753, X4-tropic), and SF162 (GenBank accession #
AY669736, R5-tropic). Z205F.ENV1.1 0Mfounder (GenBank ac-
cession #GQ485415, R5-tropic) Z205FENV6.3 0Mescape Gen-
Bank accession #GQ485419, R5-tropic), Z205FENV2.3 8Mescape
(GenBank accession # GQ485425, R5-tropic), Z205FENV5.1
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FENV4.1 38Mescape GenBank accession # GQ485447, R5-tropic)
QA203M1 (GenBank accession #DQ136332, R5-tropic)
QA203M41 (GenBank accession #DQ136341, R5-tropic), Q23
(GenBank accession # AF004885, R5-tropic).
Supporting Information
Figure S1 Flow cytometry based a4b7 steady-state binding assay.
A) The a4b7-binding assay employed highly activated purified
CD4
+ T cells cultured for 6–9 days in retinoic acid. a4b7
expression was monitored by staining cells with CD45RO and the
b7 mAb FIB27. B) Gating on the CD45RO/CCR5 population
was carried out in order to analyze gp120 binding to a4b7 high
CD4
+ T cells. C) a4b7-reactivity was reported as the mean
fluorescence intensity of biotinylated gp120s binding to the
CCR5
+/CD45RO
+ cell subset. Binding assays were carried out
in the presence of an unlabeled CD4 mAb (Leu3A/SK3) in order
to block gp120 binding to CD4. Where specified an unlabeled a4
mAb (HP2/1) was used to mask a4b7. Specificity was demon-
strated by masking with both mAbs. D) In most assays gp120
reactivities, in the presence of excess unlabeled Leu3A, were
measured over a range of concentrations, and steady-state
reactivity was determined following a 30-minute incubation at
4uC. HP2/1 was included along with Leu3A as a specificity
control, where indicated.
Found at: doi:10.1371/journal.ppat.1001301.s001 (2.46 MB TIF)
Figure S2 Comparison of the a4b7-reactivity of CHO-S vs.
293F produced gp120. Flow-cytometry based measurement of the
a4b7-reactivity of CAP881m.C12 gp120 expressed in either CHO-
S cells or 293F cells. Reactivity to both CD4 and a4b7 was
measured by differentially masking each receptor with unlabeled
mAbs. Values reported reflect mean fluorescence intensity (MFI).
These results are representative of three independent experiments.
Found at: doi:10.1371/journal.ppat.1001301.s002 (0.13 MB TIF)
Figure S3 The effect of Endoglycosydase H treatment of AN1
gp120 on a4b7-reactivity. AN1 gp120 (subtype B) was either mock-
or endoglycosidase H-digested for 50 and 250 minutes, and a4b7-
reactivity was determined by binding to a4b7 high CD4
+ T cells as
described in Figure S1. Values reported reflect mean fluorescence
intensity (MFI). These results are representative of three
independent experiments.
Found at: doi:10.1371/journal.ppat.1001301.s003 (0.13 MB TIF)
Figure S4 Amino acid sequences of early-transmitting gp120s
and neutralization escape variants. The V1/V2 sequences of
patient 205F gp120s analyzed in this study, and the V1/V2 and
C3/V4 sequences of the patient CAP88 gp120s analyzed in this
study deposited in GENBANK by the referenced investigators.
Amino acid substitutions in the CAP88 12 month isolate that
contribute to Nab escape are highlighted in red.
Found at: doi:10.1371/journal.ppat.1001301.s004 (0.57 MB TIF)
Figure S5 Surface plasmon resonance analysis of sCD4 (D1D2)
binding to immobilized gp120s. Sensorgrams depicting the
binding kinetics of increasing concentrations of monomeric
sCD4 D1D2 reacting with a panel of immobilized gp120s. Each
ligand/analyte pair is listed and overall affinity is reported as both
KD and KA. On-rates (ka) and off-rates (kd) are also listed.
Found at: doi:10.1371/journal.ppat.1001301.s005 (1.44 MB TIF)
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